KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Payables (2016 - 2025)

Historic Payables for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Q3 2025 value amounting to $21.7 million.

  • Acadia Pharmaceuticals' Payables rose 1397.2% to $21.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.7 million, marking a year-over-year increase of 1397.2%. This contributed to the annual value of $16.2 million for FY2024, which is 770.11% down from last year.
  • Acadia Pharmaceuticals' Payables amounted to $21.7 million in Q3 2025, which was up 1397.2% from $20.1 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' Payables' 5-year high stood at $21.7 million during Q3 2025, with a 5-year trough of $6.9 million in Q4 2021.
  • In the last 5 years, Acadia Pharmaceuticals' Payables had a median value of $16.2 million in 2024 and averaged $14.7 million.
  • The largest annual percentage gain for Acadia Pharmaceuticals' Payables in the last 5 years was 12247.19% (2021), contrasted with its biggest fall of 1903.92% (2021).
  • Over the past 5 years, Acadia Pharmaceuticals' Payables (Quarter) stood at $6.9 million in 2021, then surged by 85.37% to $12.7 million in 2022, then surged by 37.64% to $17.5 million in 2023, then fell by 7.7% to $16.2 million in 2024, then soared by 34.31% to $21.7 million in 2025.
  • Its last three reported values are $21.7 million in Q3 2025, $20.1 million for Q2 2025, and $18.1 million during Q1 2025.